{"id":635038,"date":"2023-01-23T16:04:01","date_gmt":"2023-01-23T16:04:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=635038"},"modified":"2023-01-23T16:04:01","modified_gmt":"2023-01-23T16:04:01","slug":"developmental-and-epileptic-encephalopathy-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/developmental-and-epileptic-encephalopathy-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight_635038.html","title":{"rendered":"Developmental and Epileptic Encephalopathy Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1674452292.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Developmental and Epileptic Encephalopathy Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1674452292.jpeg\" alt=\"Developmental and Epileptic Encephalopathy Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Developmental and Epileptic Encephalopathy Pipeline Insights<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">United States, Nevada, Las Vegas, DelveInsight\u2019s &#8216;Developmental and Epileptic Encephalopathy Pipeline Insight 2022&#8217; report provides comprehensive global coverage of available, marketed, and pipeline Developmental and Epileptic Encephalopathy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Developmental and Epileptic Encephalopathy pipeline domain.<\/div>\n<p style=\"text-align: justify;\">United States, Nevada, Las Vegas, DelveInsight&rsquo;s <strong>&#8216;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/developmental-and-epileptic-encephalopathies-dee-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Developmental and Epileptic Encephalopathy Pipeline Insight 2023<\/strong><\/a><strong>&#8216;<\/strong> report provides comprehensive global coverage of available, marketed, and pipeline Developmental and Epileptic Encephalopathy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Developmental and Epileptic Encephalopathy pipeline domain.<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/developmental-and-epileptic-encephalopathies-dee-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\">Developmental and Epileptic Encephalopathy Pipeline Report<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Over 10+ Developmental and Epileptic Encephalopathy pipeline therapies are in various stages of development, and their anticipated acceptance in the Developmental and Epileptic Encephalopathy market would significantly increase market revenue.&nbsp;<\/li>\n<li>Leading Developmental and Epileptic Encephalopathy companies developing novel drug candidates to improve the Developmental and Epileptic Encephalopathy treatment landscape include <strong>Jazz Pharmaceuticals, Biocodex, Zogenix (Acquired by UCB), Lundbeck, <\/strong>and others.<\/li>\n<li>Promising Developmental and Epileptic Encephalopathy pipeline therapies in various stages of development include<strong> Epidiolex (Cannabidol), Diacomit (Stiripentol), Fintepla (Fenfluramine), Sabril (Vigabatrin), <\/strong>and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Developmental and Epileptic Encephalopathy Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Developmental and Epileptic Encephalopathy (DEE) refers to a group of severe epilepsies that are characterized both by seizures, which are often drug-resistant, as well as encephalopathy, which is a term used to describe significant developmental delay or even loss of developmental skills. The syndromes of epileptic encephalopathies with onset in the neonatal period, infancy, and early childhood include early myoclonic encephalopathy, Ohtahara syndrome, West syndrome, Dravet syndrome (severe myoclonic epilepsy in infancy), Lennox&ndash;Gastaut syndrome (LGS), Landau&ndash;Kleffner syndrome (LKS), Epilepsy with continuous spike-and-waves during slow-wave sleep, Doose Syndrome (myoclonic atonic epilepsy), CDKL5 deficiency disorder (CDD), Tuberous sclerosis complex (TSC), SCN8A-DEE, and KCNQ2-DEE.<\/p>\n<p style=\"text-align: justify;\"><strong>Developmental and Epileptic Encephalopathy Pipeline Analysis: Drug Profile<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Epidiolex (Cannabidol): Jazz Pharmaceuticals<\/strong><\/p>\n<p style=\"text-align: justify;\">Epidiolex (formerly GWP42003-P), also known as Epidyolex in Europe, is the first prescription, plant-derived cannabis oral formulation developed by GW pharmaceuticals. It is a novel class of antiepileptic medications with a different mechanism of action. It has been approved in the US and Europe for the treatment of seizures associated with LGS or Dravet syndrome in patients 2 years of age and older. The drug is the first FDA-approved drug that contains a purified drug substance derived from marijuana, and the active ingredient is cannabidiol (CBD).<\/p>\n<p style=\"text-align: justify;\">Discover more about the emerging Developmental and Epileptic Encephalopathy drugs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/developmental-and-epileptic-encephalopathies-dee-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Developmental and Epileptic Encephalopathy Treatment Drugs<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Developmental and Epileptic Encephalopathy Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Jazz Pharmaceuticals<\/li>\n<li>Biocodex<\/li>\n<li>Zogenix (Acquired by UCB)<\/li>\n<li>Lundbeck<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Developmental and Epileptic Encephalopathy Pipeline Therapies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Epidiolex (Cannabidol)<\/li>\n<li>Diacomit (Stiripentol)<\/li>\n<li>Fintepla (Fenfluramine)<\/li>\n<li>Sabril (Vigabatrin)<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Developmental and Epileptic Encephalopathy Pipeline Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>By development stage<\/strong><\/li>\n<li><strong>By product type<\/strong><\/li>\n<li><strong>By route of administration<\/strong><\/li>\n<li><strong>By molecule type<\/strong><\/li>\n<li><strong>By MOA type&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Scope of the Developmental and Epileptic Encephalopathy Pipeline Report&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Coverage<\/strong>:&nbsp;Global&nbsp;<\/li>\n<li><strong>Key Developmental and Epileptic Encephalopathy Companies<\/strong>: Jazz Pharmaceuticals, Biocodex, Zogenix (Acquired by UCB), Lundbeck, and others<\/li>\n<li><strong>Key Developmental and Epileptic Encephalopathy Pipeline Therapies<\/strong>: Epidiolex (Cannabidol), Diacomit (Stiripentol), Fintepla (Fenfluramine), Sabril (Vigabatrin), and others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Find out more about the Developmental and Epileptic Encephalopathy treatment options in development @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/developmental-and-epileptic-encephalopathies-dee-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Developmental and Epileptic Encephalopathy Clinical Trials<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Overview<\/p>\n<p style=\"text-align: justify;\">4. Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">5. Late-Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\">6. Mid-Stage Products (Phase&nbsp; II)<\/p>\n<p style=\"text-align: justify;\">7. Early Stage Products (Phase&nbsp; I\/II)<\/p>\n<p style=\"text-align: justify;\">8. Preclinical Stage Products<\/p>\n<p style=\"text-align: justify;\">9. Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">11. Inactive Products<\/p>\n<p style=\"text-align: justify;\">12. Collaborations Assessment- Licensing \/ Partnering \/ Funding<\/p>\n<p style=\"text-align: justify;\">13. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">14. Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">15. Appendix<\/p>\n<p style=\"text-align: justify;\">16. About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>Request for a sample report to know more about the leading companies in the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/developmental-and-epileptic-encephalopathies-dee-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\">diabetic epileptic encephalopathy pipeline domain<\/a>.<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=developmental-and-epileptic-encephalopathy-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=developmental-and-epileptic-encephalopathy-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Developmental and Epileptic Encephalopathy Pipeline Insights United States, Nevada, Las Vegas, DelveInsight\u2019s &#8216;Developmental and Epileptic Encephalopathy Pipeline Insight 2022&#8217; report provides comprehensive global coverage of available, marketed, and pipeline Developmental and Epileptic Encephalopathy therapies in various stages of clinical development, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/developmental-and-epileptic-encephalopathy-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight_635038.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-635038","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/635038","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=635038"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/635038\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=635038"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=635038"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=635038"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}